Patients with end-stage liver disease suitable for liver transplantation and their liver donors
Conditions
Interventions
None listed
Sponsors
Uchida Koichiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients who have given written informed consent to participate in the clinical trial. (2) Male or Female patients aged between 20 and 80 years old at the time of obtaining informed consent. (3) Patients who have been approved or will be approved for living-donor liver transplantation at the Medical Ethics Committee or equivalent organization established by the institution. (4) Patients who have not used the investigational drug, device or product within 3 months of obtaining consent.(recipient) (5) Patients who have not previously used JB-101 and do not plan to use it during the study subject observation period.(recipient) (6) Patients who are judged by principal investigators or sub-investigators, to be able to carry out the observation for the period specified in this research, based on the place of residence, etc.
Exclusion criteria
Exclusion criteria: -
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Serious adverse events from the date of liver transplantation to the time of final observation 2) Serious side effects from the date of liver transplantation to the time of final observation 3) Immunosuppressant-related side effects of particular note from the date of liver transplantation to the time of final observation etc. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Incidence rate of rejection after transplantation 2) Incidence of no rejection 3) Patient survival rate etc. | — |
Contacts
Public ContactSaori Hirota
Juntendo University
Outcome results
None listed